Commonwealth Equity Services
NRXP icon

Commonwealth Equity Services’s NRX Pharmaceuticals NRXP Stock Holding History

Commonwealth Equity Services’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$847K Buy
397,431
+30,800
+8% +$62.2K ﹤0.01% 2742
2025
Q4 		$994K Buy
+366,631
New +$984K ﹤0.01% 2582

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return

Commonwealth Equity Services's NRXP Position: Q1 2026 in Review

Commonwealth Equity Services increased its NRX Pharmaceuticals (NRXP) stake by 8.4% in Q1 2026, buying an estimated $62.2K and bringing the position to 397,431 shares worth $847K. The position accounts for ﹤0.01% of the portfolio, ranked #2742.

Commonwealth Equity Services first reported a position in NRXP in Q4 2025 and has held it in 2 quarters since. The position peaked at $994K in Q4 2025. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • Commonwealth Equity Services held 397,431 shares of NRX Pharmaceuticals worth $847K as of Q1 2026.
  • Commonwealth Equity Services bought 30,800 NRX Pharmaceuticals shares in Q1 2026, an estimated $62.2K.
  • NRX Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #2742 holding.
  • Commonwealth Equity Services first reported a position in NRX Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Commonwealth Equity Services's NRX Pharmaceuticals position peaked at $994K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.